Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 2Phase 3 2

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 9Prostatic Neoplasms 6Neoplasms 6Multiple Myeloma 4Fractures, Bone 4Osteoporosis 3Bone Diseases, Metabolic 3Spinal Cord Compression 2Giant Cell Tumor of Bone 2Bone Metastases 2Bone Diseases 2Parathyroid Neoplasms 1Paraproteinemias 1Neoplastic Processes 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Mastocytosis, Systemic 1Lymphoma 1Hyperparathyroidism, Primary 1Hormone Refractory Prostate Cancer 1Hematologic Neoplasms 1Hematologic Diseases 1Cataract 1Castrate-resistant Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Diseases 1Bone Neoplasms 1

Interventions

Denosumab 2Zoledronic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Giant Cell Tumor of Bone × Denosumab × Clear all
NCT05813665 2023-04-19

A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone

Shanghai JMT-Bio Inc.

Phase 3 Not yet recruiting
146 enrolled

Giant Cell Tumor of Bone

NCT03259152 2017-08-24

D-Gct

Hebei Medical University Third Hospital

Phase 3 Unknown
30 enrolled

Giant Cell Tumor of Bone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡